How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

345 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

-containing preparations such as cough syrups, tonics etc. Current use of tipranavir or Maraviroc Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has potent irreversible inhibitory effects on mitochondrial metabolism and hence could exacerbate the toxicity of these drugs) Concurrent use of rivaroxaban (a CYP3A metabolized medication) as the cytochrome P450 inhibitory effects of disulfiram on rivaroxaban are unknown Current use of warfarin Individuals who intend to modify

2017 Clinical Trials

82. The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

, quinidine, and pyrimethamine) Riociguat (guanylate cyclase stimulant) Alpha blockers Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine patches) Potent CYP3A4 inhibitors (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir) All antihypertensive medications Medications associated with weight changes Drugs approved for the treatment of obesity Cypropheptadine

2017 Clinical Trials

83. Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

HCV Genotype 1, 2, 3, 4, 5 or 6 Otherwise eligible for lung transplant at study site Exclusion Criteria: Age <18 Treatment with any of the following agents: Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 SOF/VEL Carbamazepine, phenytoin, phenobarbital, oxcarbazepine Rifabutin, rifampin or rifapentine HIV regimens containing tenofovir or tipranavir/ritonavir St John's wort PPIs, including: Omeprazole, pantoprazole

2017 Clinical Trials

84. A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

of the investigator and the sponsor. Gastrointestinal disorder affecting absorption. Current or anticipated use within 7 days prior to first dose of study drug or anticipated use during the study of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar). Any other acute or chronic

2017 Clinical Trials

85. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

NVP nevirapine OST opioid substitution therapy PCr polymerase chain reaction PI protease inhibitor PICO Population, Intervention, Comparison and Outcomes PCP/PJP Pneumocystis (jirovecii) pneumonia PMTCT prevention of mother-to-child transmission of HIV PrEP pre-exposure prophylaxis of HIV rAL raltegravir r BV ribavirin rIF rifampicin r NA ribonucleic acid rTV ritonavir sd-NVP single-dose nevirapine TAM thymidine analogue mutation TB tuberculosis TDF tenofovir disoproxil fumarate TPV tipranavir

2013 World Health Organisation HIV Guidelines

87. Antiepileptic drug selection for people with hiv/aids

interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus . 24. Okulicz JF , Grandits GA , French JA , et al . Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study . Bates DE , Herman RJ . Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir . 26. Bonora S , Calcagno A , Fontana S , et al . Clinically significant drug interaction between tipranavir-ritonavir

2012 American Academy of Neurology

88. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

) or plans to participate in an experimental drug study while enrolled in this study. The participant is on a concomitant medication that is a strong CYP3A4 inhibitor. These include, but are not limited to: larithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2016 Clinical Trials

89. Hepatitis C Virus(HCV) Heart and Lung Study

with chronic hypercapnia (baseline partial pressure of arterial carbon dioxide [PaCO2] > 45) Exclusion Criteria: Chronic HCV Infection with Genotype 2 or 3 Treatment with any of the following agents Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 of SOF/LDV FDC Carbamazepine, phenytoin, phenobarbital, oxcarbazepine Rifabutin, rifampin or rifapentine HIV regimens containing tenofovir or tipranavir/ritonavir St. John's wort Rosuvastatin

2016 Clinical Trials

90. Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

/Antivirals (e.g. rotanavir or plus rotanavir, tipranavir, lopinavir, boceprevir, saquinovir, darunavir, fosamprenavir, nelfinavir, efavirenz/tenofobir, atazanavir, simeprevir); Hep C Protease Inhibitor/Antivirals (e.g. telapravir); Antibiotics (i.e. cobicistat-containing products like Tybost, rifampin/rifampicin, clarithromycin, telithromycin, erythromycin); Anti-fungals (i.e. itraconazole, ketoconazole, posaconazole, voriconazole, fluconazole); *Gemfibrozil; Other Fenofibrates (e.g. Tricor, fibric acid

2016 Clinical Trials

91. Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

days before the first dose of study drug. Patients who are taking and are required to take any of the following agents that are CYP3A inhibitors: Amiodarone, Erythromycin, Fluconazole, Itraconazole, Ketoconazole, Miconazole, Diltiazem, Verapamil, Amprenavir, Fosamprenavir, Clarithromycin, Telithromycin, Nefazodone, Atazanavir, Darunavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir. Contacts and Locations Go to Information from the National Library of Medicine To learn more

2016 Clinical Trials

92. Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

stable for at least 1 week prior to RHC. Treatment with other PDE-5i for erectile dysfunction. Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior to Day 1. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir, telaprevir, saquinavir, lopinavir, fosamprenavir, darunavir, tipranavir

2016 Clinical Trials

93. Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

, voriconazole, grapefruit juice (or grapefruits) Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort **Note

2016 Clinical Trials

94. Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

of tipranavir/ritonavir or fosamprenavir/ritonavir Subjects receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02951052 Sponsors and Collaborators ViiV

2016 Clinical Trials

95. Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

of immunosuppressive agents*. *including anti-neoplastic chemotherapy or cytotoxic radiation therapy for cancer, anti-TNF medications, or other immunomodulating agents. History of a solid organ or bone marrow transplant. Have poorly controlled HIV-infection or HIV-infection treated with Lopinavir, Tipranavir, Etravirine or Didanosine. Poorly controlled HIV is defined as HIV RNA > 50 copies/mm^3 (or greater than the lower limit of quantification [LLOQ] of the local HIV RNA assay if the LLOQ is > 50) in the 6 months

2016 Clinical Trials

96. Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

or planned treatment with strong inhibitors (e.g. ketoconazole, clarithromycin, etcetera [etc]) or strong inducers (e.g. carbamazepine, phenytoin, rifampin, phenobarbital, efavirenz, tipranavir, St. John's wort) of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided

2016 Clinical Trials

97. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance (PubMed)

(Atazanavir-ATV, Darunavir-DRV, Indinavir-IDV, Lopinavir-LPV, Nelfinavir-NFV, Saquinavir-SQV, and Tipranavir-TPV) showed that cross-resistance can develop easily across NFV, SQV, LPV, IDV, and DRV, but not for ATV or TPV. Through estimation of the changes in vibrational entropies caused by each reported mutation, some secondary mutations were found to destabilize protease structure. Our findings provide an insight into the mechanism of PI cross-resistance and may also be useful in guiding the selection

Full Text available with Trip Pro

2016 BMC bioinformatics

98. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4 (PubMed)

of 0.016±0.001 and 204±18 μM, respectively. Methamphetamine-CYP3A4 docking showed that methamphetamine binds to the heme of CYP3A4 in two modes, both leading to N-demethylation. We then studied the effect of methamphetamine binding on PIs with CYP3A4. Our results showed that methamphetamine alters spectral binding of nelfinavir but not the other type I PIs (lopinavir, atazanavir, tipranavir). The change in spectral binding for nelfinavir was observed at both δAmax (0.004±0.0003 vs. 0.0068±0.0001

Full Text available with Trip Pro

2016 PloS one

99. Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients (PubMed)

Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients A new method using high-performance liquid chromatography coupled with ultra violet detection (HPLC-UV) was developed and validated for the simultaneous quantification of atazanavir, dolutegravir, darunavir, efavirenz, etravirine lopinavir, raltegravir, rilpivirine and tipranavir in human plasma. For the first time we reported here the development

Full Text available with Trip Pro

2016 Journal of Pharmaceutical Analysis

100. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. (PubMed)

), and 5 and 1 % (p = 0.14) of patients in the RAL and ENF arms, respectively. The 48-week incidence of grade 2 or more LEE was 11.6 per 100-pts-years for ALT, 24.5 per 100-pts-years for γ-GT and 4.5 per 100-pts-years for ALP, respectively. In the multivariate analysis, tipranavir/ritonavir use (OR 3.66; 95 % CI [1.20-11.1], p = 0.022) and elevated ALT at baseline (OR 10.3; 95 % CI [2.67-39.6], p < 10(-3)) were significantly associated with a grade 2 or more ALT elevation during follow-up.The incidence (...) of LEE was relatively high in these highly treatment-experienced patients switching to a RAL-based regimen. Both tipranavir/ritonavir use and high baseline ALT levels were associated with an increased risk of ALT.ClinicalTrials.gov identifier: NCT00454337.

Full Text available with Trip Pro

2016 AIDS research and therapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>